SPATIAL OMICS MARKET ANALYSIS
Recent Developments
In November 2023, Stellaromics, a premier provider of in situ spatial multi-omics technology, announced the successful completion of its Series A funding round, securing US$ 25 million. This funding round saw participation from Plaisance Capital Management and a prominent Silicon Valley-based private family office, highlighting strong investor confidence in the company's innovative approach to spatial multi-omics technology.
In June 2023, OWKIN and 10x Genomics, Inc., a leading techbio company, announced that it had signed a deal to integrate 10x Genomics spatial omics and single-cell technologies into the ambitious MOSAIC project. This project has garnered acclaim for its pioneering efforts in tumor analysis aimed at advancing therapeutic discovery.
In December 2021, Rebus Biosystems, Inc., a life science technology company, revealed its acquisition of EEL Transcriptomics AB's intellectual property and associated assay assets. EEL Transcriptomics AB, a privately held enterprise specializing in high-plex spatial transcriptomics with single-cell resolution, has been the focus of this acquisition. The specific terms of the transaction have not been disclosed.
In March 2021, Rebus Biosystems, Inc. announced the launch of the Rebus Esper spatial omics platform. This cutting-edge platform empowers researchers to delve deeper into tissue biology, facilitating advancements in various fields such as neurology, oncology, infectious diseases, and immunology.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 
